MADRID--(BUSINESS WIRE)--Janssen-Cilag International NV (Janssen) announced today that four presentations on ZYTIGA® (abiraterone acetate) will be made at the 30th Annual European Association of Urology (EAU) Congress from 20th – 24th March 2015 in Madrid, Spain.
Thomas Stark, Vice-President, Medical Affairs, Janssen Europe, the Middle East and Africa said: “We look forward to sharing this range of additional data for abiraterone acetate which further investigates the safety, efficacy and tolerability profile of the treatment in both the pre and post chemotherapy settings, in patients with metastatic castration-resistant prostate cancer.
Help employers find you! Check out all the jobs and post your resume.
